Eligibility Details:  
        Inclusion Criteria
        Male and female participants who are between 18 and 45 years of age.
        Smoking group - 80 treatment-seeking smokers who self-report smoking at least 10 cigarettes
        (menthol and/or non-menthol) per day for at least the last 6 months. Smoking status will be
        confirmed by CO greater than or equal to 8 parts per million (ppm) at the Intake Visit.
        Non-smoking group - 30 individuals reporting fewer than 100 lifetime cigarettes and not
        even a puff of a cigarette for a minimum of 2 years. Smoking status of non-smokers will be
        confirmed by CO less than 5ppm. They will be matched to the smoker group on age, sex, and
        education.
        Plan to live in the area for the duration of the study (i.e. ~8 weeks/2 months).
        Capable of giving written informed consent, which includes compliance with the requirements
        and restrictions listed in the combined consent and HIPAA form.
        Smokers who wish to make a permanent quit attempt in the next 1-2 months
        (treatment-seeking), because our prior work suggests that motivated subjects are more
        sensitive to medication effects on smoking behavior. Using a scale from 0 to 100 (100,
        being extremely interested), subjects must rate their interest in quitting smoking within
        the next 1-2 months greater than 50.
        Able to communicate fluently in English (i.e. speaking, writing, and reading).
        Exclusion Criteria
        Subjects who present and/or self-report with the following criteria will not be eligible to
        participate in the study:
        Smoking Behavior
          1. Regular use of nicotine-containing products other than cigarettes (e.g. chewing
             tobacco, snuff, snus, cigars, e-cigs, etc.). Participants agreeing to abstain from
             using nicotine- containing products other than cigarettes will be considered eligible.
          2. Current enrollment or plans to enroll in another research and/or smoking cessation
             program over the duration of the study (i.e. ~8 weeks/2 months).
          3. Anticipated use (within the next ~8 weeks/2 months) of any nicotine substitutes and/or
             smoking cessation treatments/medications unless provided through the study.
          4. Provide a CO breath test reading less than 8 ppm at Intake Visit (smokers) or greater
             than 5ppm at intake visit (non-smokers).
        Alcohol and Drug
          1. History of substance abuse (other than nicotine) in the past 12 months and/or
             currently receiving medical treatment for substance abuse. Counseling and support
             groups (e.g. Alcoholics Anonymous and Narcotics Anonymous) will not be considered
             medical treatment for the purposes of this protocol.
          2. Current alcohol consumption that exceeds 25 standard drinks/week.
          3. Breath alcohol reading (BrAC) greater than .000 at the Intake Visit.
          4. A positive urine drug screen (UDS) for cocaine, opiates, amphetamines,
             methamphetamines, phencyclidine (PCP), ecstasy (MDMA), barbiturates, benzodiazepines,
             methadone, and/or oxycodone at the Intake Visit.
        Medical
          1. Women who are pregnant, breast feeding, or planning a pregnancy over the duration of
             the study period. Women must agree to use an adequate form of contraception or abstain
             from sexual intercourse for the duration of the study.
          2. Current treatment of cancer or diagnosed with cancer (except basal or squamous-cell
             carcinoma not treated with chemotherapy and/or radiation) in the past 6 months.
          3. Poorly controlled, brittle, or pump-dependent Type I diabetes.
          4. Current peptic ulcer bleeding.
          5. Active hepatitis or poorly controlled kidney and/or liver disease.
          6. Serious or unstable disease within the past 6 months. Notable diseases will be
             evaluated on a case-by-case basis by the Principal Investigator and/or the Study
             Physician.
          7. Any impairment including, but not limited to, visual, physical, and/or neurological
             impairments preventing proper completion of the study procedures. Notable impairments
             will be evaluated on a case-by-case basis by the Principal Investigator and/or the
             Study Physician.
          8. Applicable food allergies or disorders:
               -  Galactosemia a
               -  Notable milk allergy (lactose intolerant participants may proceed unless they
                  experience severe symptoms) b
               -  Notable soy allergy c
               -  Peanut allergy d a,b,c Boost® Original Very Vanilla Nutritional Shake: Contains
                  milk and soy ingredients. Suitable for Lactose Intolerance.
                    1. b,c,d M&M's® (Milk Chocolate): Contains milk and soy ingredients (MAY
                       CONTAIN PEANUTS) Lay's® Classic Potato Chips (Gluten Free): Potatoes,
                       vegetable oil, and salt
        Psychiatric
          1. Current diagnosis of major depression. Subjects with a history of major depression, in
             remission for 6 months or longer (may be stable on antidepressant medications), are
             eligible.
          2. Lifetime history of a suicide attempt.
          3. Lifetime history of schizophrenia, psychosis, and/or bipolar disorder.
          4. Current diagnosis of Attention Deficit/Hyperactivity Disorder (ADHD).
          5. Current diagnosis of bulimia, anorexia nervosa or binge eating.
        Medication
        Current use or recent discontinuation (within the last 14 days) of:
          1. Smoking cessation medication (e.g., Zyban, Wellbutrin, Wellbutrin SR, Chantix).
          2. Benzodiazepines and/or Barbiturates.
          3. Anti-psychotic medications.
          4. Prescription stimulants (e.g., Provigil, Ritalin, Adderall).
          5. Systemic steroids.
          6. Medications for the use of addiction treatment.
             Current use of:
          7. Nicotine replacement therapy (NRT).
          8. Heart medications such as digoxin, quinidine, and nitroglycerin.
             Daily use of:
          9. Opiate-containing medications for chronic pain.
         10. Inhaled corticosteroids.
        Subjects will be instructed to refrain from using any study-prohibited drugs/medications
        (both recreational and prescription) throughout their participation in the study. After
        final eligibility is confirmed, subjects who report taking contraindicated medication(s)
        over the course of the study period may only remain eligible if the Study Physician and
        Principal Investigator determine that the contraindicated medication(s) do/did not
        significantly impact the study design, data quality, and/or subject safety and welfare.
        Subjects are permitted to take necessary prescription medications not included within the
        exclusion list during the study.
        General Exclusion
          1. Past, current, anticipated, or pending enrollment in another research program over the
             study period that could potentially impact subject safety, study data, and/or the
             study design as determined by the Principal Investigator and/or Study Physician.
          2. Participation in a dietary program within the past 30 days.
          3. Any medical condition, illness, disorder, adverse event (AE), or concomitant
             medication that could compromise participant safety or significantly impact study
             performance as determined by the Principal Investigator and/or Study Physician.
             Subjects may be deemed ineligible for any of the aforementioned reasons at any point
             throughout the study, as well as during the initial telephone screen.
          4. Significant non-compliance with protocol and/or study design as determined by the
             Principal Investigator and/or Study Physician. Subjects may be deemed ineligible at
             any point throughout the study.
          5. Low or borderline intellectual functioning - determined by receiving a score of less
             than 85 on the Shipley Institute of Living Scale (SILS), which correlates with the
             Wechsler Adult Intelligence Scale-Revised (WAIS-R) Estimated IQ Test.
        fMRI Exclusion Criteria
          1. History of claustrophobia.
          2. Being left-handed.
          3. Lifetime history of stroke.
          4. Having a cochlear implant or wearing bilateral hearing aids.
          5. History of notable head trauma. Although notable head trauma is typically defined as
             being knocked unconscious for a period of three minutes or longer, notable head trauma
             will be evaluated on a case-by-case basis by the appropriate personnel prior to an
             eligibility decision, considering exceptions can be made based on the nature and
             severity of the trauma.
          6. History of brain or spinal tumor.
          7. Pacemakers, certain metallic implants or objects, or presence of metal in the eye as
             contraindicated for MRI.
          8. Any circumstances (e.g., exclusionary metal implants, certain dental work, and/or
             physical impairments) and/or conditions that may interfere with MRI and MRI-related
             study visit procedures. All potential exclusionary circumstances and/or conditions
             will be evaluated on a case-by-case basis by the appropriate personnel prior to an
             eligibility decision.
          9. History of gunshot wounds. Injuries from BB guns will be evaluated on a case-by-case
             basis by the appropriate personnel prior to an eligibility decision.
         10. History of epilepsy and/or recurrent or uncontrolled seizures.
         11. Weight greater than 250 lbs at Intake Visit or self-reported at phone screen. If a
             participant weighs less than or equal to 250 lbs at Intake, but presents with a weight
             greater than 250 lbs at either Scan 1 and/or Scan 2, the participant may be permitted
             to proceed with the scan as long as the participant's weight does not exceed 300 lbs.
         12. A positive urine drug screen (UDS) for cocaine, opiates, amphetamines,
             methamphetamines, phencyclidine (PCP), ecstasy (MDMA), barbiturates, benzodiazepines,
             methadone, and/or oxycodone at intake or either Scan Visit.
         13. A BrAC greater than 0.000 at intake or either Scan Visit.